Diplomat Pharmacy, Inc. announced that full-year 2018 revenues and Total Adjusted EBITDA are not impacted by any impairment charge and the company’s previously communicated outlook of 2018 revenues of $5.5 - $5.6 billion and 2018 EBITDA of $167 - $170 million remain unchanged. However, the company has withdrawn its preliminary 2019 full-year outlook provided in January.